Aquestive Therapeutics, Inc. (AQST) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Aquestive Therapeutics is a pharmaceutical company focused on developing and manufacturing complex molecule-based products using proprietary delivery technologies. Key commercial activities include the manufacturing of licensed products (e.g., Suboxone for Indivior) and the commercialization of its proprietary product, Libervant (diazepam buccal film), which was launched in April 2024 for pediatric epilepsy patients aged two to five. The company is also advancing its pipeline, notably Anaphylm (epinephrine sublingual film) for anaphylaxis and AQST-108 (epinephrine topical gel) for alopecia areata.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenues | $13,542 | $13,002 | $45,694 | $37,377 |
| Net Loss | $(11,509) | $(2,035) | $(27,082) | $241 |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.03) | $(0.32) | $0.00 |
| Cash and Cash Equivalents | $77,893 | $24,917 | $77,893 | $24,917 |
| Notes Payable, Net | $31,253 | $27,508 | $31,253 | $27,508 |
| Royalty Obligations, Net | $18,835 | $14,761 | $18,835 | $14,761 |
| Operating Cash Flow (9M) | $(29,270) | $(1,438) | $(29,270) | $(1,438) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4% in Q3 and 22% for the nine months ended September 30, 2024, compared to the prior year. This was driven primarily by a 314% increase in license and royalty revenue due to the one-time recognition of deferred revenue from terminated agreements (Haisco and MTPA).
- Expense Increases: Operating expenses rose significantly. Selling, general, and administrative (SG&A) expenses increased 64% in Q3 and 54% for the nine months, driven by higher personnel costs, share-based compensation, and regulatory fees for Libervant. Research and development (R&D) expenses increased 65% in Q3 and 50% for the nine months, primarily due to clinical trial costs for the Anaphylm program.
- Net Loss Expansion: The net loss widened to $11.5 million in Q3 2024 from $2.0 million in Q3 2023. This was exacerbated by increased interest expense (up 121% in Q3) due to the amortization of debt issuance costs and discounts on the 13.5% Senior Secured Notes issued in late 2023.
- Liquidity Improvement: Cash and cash equivalents increased to $77.9 million from $23.9 million at year-end 2023, bolstered by a $72.9 million underwritten public offering in April 2024 and ATM facility sales.
Guidance, Outlook, and Risks
- Product Pipeline: Management expects to submit a New Drug Application (NDA) for Anaphylm in Q1 2025, with a potential launch in Q1 2026 if approved. A pre-NDA meeting with the FDA is scheduled for Q4 2024. AQST-108 is advancing toward a Phase 2a study in Q2 2025.
- Libervant Commercialization: The company is expanding market access for Libervant in the U.S. for pediatric patients (ages 2-5). However, market access for patients aged 6 and older remains blocked by orphan drug exclusivity until January 2027, unless the company can demonstrate clinical superiority.
- Liquidity Outlook: Management states that existing cash, combined with access to equity markets (ATM facility), provides sufficient liquidity to fund operations for at least the next 12 months.
- Key Risks:
- Legal Proceedings: The company is a defendant in over 560 product liability lawsuits regarding dental injuries from Suboxone (consolidated in MDL) and faces litigation from Neurelis regarding the FDA approval of Libervant.
- Debt Obligations: The company carries significant debt, including 13.5% Senior Secured Notes due 2028 and royalty obligations. Principal payments on the notes begin in June 2026.
- Customer Concentration: Indivior represented approximately 59% of total revenue for the nine months ended September 30, 2024.
Investor Verification Checklist
- Debt Service Capacity: Verify the company's ability to service the 13.5% Notes and associated royalty obligations given the current burn rate and lack of profitability.
- Anaphylm Regulatory Path: Monitor the outcome of the Q4 2024 pre-NDA meeting with the FDA and the subsequent NDA submission timeline.
- Suboxone Litigation Exposure: Assess the potential financial impact of the multidistrict litigation (MDL) regarding dental injuries, noting that Indivior has agreed to defend the company.
- Revenue Sustainability: Evaluate the sustainability of revenue growth given the one-time nature of the deferred revenue recognition from terminated agreements and the declining market share of Suboxone due to generics.
- Libervant Market Access: Track progress on overcoming the orphan drug exclusivity block for the 6+ age demographic, which is critical for the product's full commercial potential.